https://daclatasvirinhibitor.c....om/genome-wide-have-
We compared BKV-ELISPOT results against five BKV peptides (big cyst antigen [LT], St, VP1-3). Outcomes BKV-ELISPOT outcomes were higher in three KTRs groups with various BKV infection status than the HCs group (p less then 0.05). In KTR teams, these were greater in cleared viremia group than no viremia or BK viremia team. Inside the BK viremia group, operator group had higher LT-ELISPOT outcomes compared to noncontroller group (p = 0.032). Also
Mi piace
Commento
Condividi
